Drug Trial Radar · NCT06066099
Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969
Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Oct 4, 2023
Primary completion
Mar 14, 2025
Study completion Mar 14, 2025
Sponsor
- Lead sponsor
- Acesion PharmaIndustry
- Sponsor type
- Industry
- First posted
- Oct 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the safety and tolerability of single doses (Part A) and multiple doses (Part B) of AP31969 in healthy participants.
Conditions
- Healthy Volunteers
Interventions
AP31969Drug
Oral tablets
PlaceboDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants who Experienced an Adverse EventTime frame: Up to a maximum of 48 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acesion Pharma Investigational Site 10
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.